All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma

May 2nd 2024

Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.

Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management

May 2nd 2024

Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.

Multidisciplinary Collaboration Plays Key Role in Pancreatic Cancer

May 2nd 2024

Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.

Risk Factors Could Inform BTK Inhibitor and Venetoclax Sequencing in CLL/SLL

May 2nd 2024

Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.

ADCs and Immunotherapy Broaden the Bladder Cancer Treatment Paradigm

May 2nd 2024

Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.

Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL

May 2nd 2024

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

Fox Chase Cancer Center Researchers Show Estrogen Metabolites Contribute to Development of Lung Cancer Among People Who Never Smoked

May 2nd 2024

Fox Chase Cancer Center researchers showed that estrogen is metabolized in lungs, contributing to the development of lung cancer in never smokers.

Eftilagimod Alpha–Based Triplet Is Well Tolerated, Generates Responses in Soft Tissue Sarcoma

May 2nd 2024

Eftilagimod alpha plus radiotherapy and pembrolizumab was safe and displayed initial activity in soft tissue sarcoma.

Adjuvant Multipeptide Vaccine Combination Prolongs Survival in Melanoma

May 2nd 2024

A multipeptide vaccine combination approach with 12MP plus 6MHP vs 12MP plus tet extended overall survival in patients with stage IIB to IV melanoma.

N-803/BCG Approval Signals Paradigm Shift in Management of BCG-Unresponsive NMIBC

May 1st 2024

Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.

Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer

May 1st 2024

A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.

Final USPSTF Recommendation Statement Advises Women Begin Receiving Mammograms at 40 Years Old

May 1st 2024

The United States Preventive Services Task Force final breast cancer screening recommendation statement advises that women aged 40 begin biennial screening.

Utah Governor’s Medal Given to Neli Ulrich, PhD, MS, for Outstanding Research and Leadership

May 1st 2024

Neli Ulrich, PhD, MS, of Huntsman Cancer Institute, has been awarded the 2024 Governor’s Medal for Science and Technology.

SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease

May 1st 2024

SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.

EVT801 Is Well Tolerated, Elicits Disease Control in Advanced Ovarian Cancer

May 1st 2024

Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.

Frontline Pembrolizumab Plus Trastuzumab/Chemo Meets OS End Point in HER2+ Gastric/GEJ Cancer

May 1st 2024

Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.

Immunogenomics Demonstrate Predictive Capability to Immunotherapy Resistance in Uveal Melanoma

May 1st 2024

Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma.

Giants of Cancer Care® Announces the 12th Annual Class of Inductees

May 1st 2024

The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.

Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC

April 30th 2024

Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.

Patient Factors, Toxicities Key to Selecting NALIRIFOX or Other Chemo Options in Advanced Pancreatic Cancer

April 30th 2024

Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.